Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2016 - 2026)
Catalyst Pharmaceuticals filings provide 17 years of Depreciation & Amortization (CF) readings, the most recent being $70000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 39.13% to $70000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $330000.0, a 22.54% decrease, with the full-year FY2025 number at $375000.0, down 5.54% from a year prior.
- Depreciation & Amortization (CF) hit $70000.0 in Q1 2026 for Catalyst Pharmaceuticals, down from $72000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $116000.0 in Q2 2025 to a low of $34000.0 in Q1 2022.
- Median Depreciation & Amortization (CF) over the past 5 years was $81000.0 (2023), compared with a mean of $76411.8.
- Biggest five-year swings in Depreciation & Amortization (CF): tumbled 64.95% in 2022 and later soared 140.0% in 2023.
- Catalyst Pharmaceuticals' Depreciation & Amortization (CF) stood at $35000.0 in 2022, then soared by 140.0% to $84000.0 in 2023, then soared by 35.71% to $114000.0 in 2024, then tumbled by 36.84% to $72000.0 in 2025, then fell by 2.78% to $70000.0 in 2026.
- The last three reported values for Depreciation & Amortization (CF) were $70000.0 (Q1 2026), $72000.0 (Q4 2025), and $72000.0 (Q3 2025) per Business Quant data.